Study Comparing Two Different Schedules of Radiation for Early-stage Lung Cancer (NCT03706027)

🧪 Interventions in This Study

• radiation therapy-3 fractions (DEVICE)
• Radiation therapy-5 fractions (DEVICE)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Histological confirmation of non-small cell cancer will not be required as primary goal of this phase II trial is to look at toxicity. However, all primary non-small cell lung cancers otherwise of following types are eligible: squamous cell carcinoma, adenocarcinoma, large cell carcinoma, bronchioalveolar cell carcinoma, or non-small cell carcinoma not otherwise specified.
2. Eligible patients must have appropriate staging studies identifying them as specific subsets of AJCC stage I or II based on only one of the following combinations of TNM staging:
3. T1, N0, M0
4. T2 (≤ 5 cm), N0, M0
5. Patients with hilar or mediastinal lymph nodes ≤ 1cm and no abnormal hilar or mediastinal uptake on PET will be considered N0. Patients with \> 1 cm hilar or mediastinal lymph nodes on CT or abnormal PET (including suspicious but non-diagnostic uptake) may still be eligible if directed tissue biopsy of all abnormally identified areas are negative for cancer. All patients with suspicious nodes will be evaluated for mediastinal and hilar staging with bronchoscopy and (if amenable) bronchoscopic biopsy (preferably navigational biopsy and/or endobronchial US guided biopsy).
6. Zubrod performance status 0-2 within 4 weeks of study entry.
7. Women of childbearing potential and male participants must use an effective contraceptive method.
8. Evaluations required at time of study entry:
9. History \& Physical by a radiation oncologist within 4 weeks of study entry;
10. Vitals within 4 weeks of study entry;
11. Evaluation by a thoracic surgeon (either via clinical examination and/or input at multidisciplinary tumor board) prior to study entry;
12. PFTs: Routine spirometry, lung volumes, diffusion capacity, and arterial blood gases within 8 weeks prior to study entry;

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

• James P. Wilmot Cancer Center at University of Rochester Medical Center — Rochester, New York

📞 Contact the Study Coordinator

Phone: (585) 275-5623

Email: deepinder_singh@urmc.rochester.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Lung Cancer

• Precision Lung Cancer Survivorship Care Intervention — Lexington, Kentucky
• Implementation Strategies for Monitoring Adherence in Real Time — Philadelphia, Pennsylvania
• Study of Trilaciclib and Lurbinectidin — Lebanon, New Hampshire
• Deep Learning Using Chest X-Rays to Identify High Risk Patients for Lung Cancer Screening CT — Boston, Massachusetts
• Early Detection of Lung Cancer — Nashville, Tennessee

Explore by condition: All Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.